You just read:

Viking Therapeutics Announces Promising Top Line Results from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH)

News provided by

Viking Therapeutics, Inc.

Jun 06, 2017, 07:14 ET